Galileo Partners Picked Aytu Bioscience Inc. (OTCMKTS:AYTU) Shares

0
17

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Aytu Bioscience Inc. (OTCMKTS:AYTU) reported that Galileo Partners, Llc. has picked up 876,250 of common stock as of 2017-05-12.

The acquisition brings the aggregate amount owned by Galileo Partners, Llc. to a total of 876,250 representing less than 7.8% stake in the company.

For those not familiar with the company, Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company’s pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men.

A glance at Aytu Bioscience Inc. (OTCMKTS:AYTU)’s key stats reveals a current market capitalization of 9.43 Million based on 13.84 Million shares outstanding and a price at last close of $0.700 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-11-02, Cantrell picked up 33,333 at a purchase price of $1.50. This brings their total holding to 98,333 as of the date of the filing.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Aytu Bioscience Inc. (OTCMKTS:AYTU) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.